Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome

Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’s Disease

Anavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients for Rett Syndrome

Rett Syndrome Association of Australia and Anavex Life Sciences Announce Initiation of the Phase 2 AVATAR Clinical Study in Patients with Rett Syndrome